Monitoring side effects of radiotherapy in metastatic cancer patients using wearable technology
Official title: Patient Reported Outcomes/Metrics Program Trial - Palliative Radiation
Run by University Health Network, Toronto · NCT04983199 · Data updated 2026-11-12
This study is testing if a wearable device can help track vital signs and activity levels in patients with metastatic cancer undergoing radiotherapy to better manage side effects and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | November 24, 2022 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT04983199 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a known cancer diagnosis who are scheduled to receive palliative radiotherapy and can use the Hexoskin Medical Shirt.
✕Probably not a fit
Patients receiving whole brain radiotherapy, those with major cognitive impairments, or those with certain medical devices like pacemakers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to recruit 100 patients undergoing palliative radiotherapy for metastatic cancer to wear the Hexoskin Medical System. The study will assess the feasibility of using this wearable technology to monitor vital signs and activity levels, which may help in the early detection and management of radiotherapy-related side effects. By combining objective data with patient-reported outcomes, the study seeks to enhance the evaluation of treatment effects and improve patient care. Participants will also complete questionnaires to provide insights into their quality of life and pain management.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of side effects from radiotherapy, enhancing the quality of life for patients with metastatic cancer.
How similar studies have gone: While the use of wearable technology in monitoring health outcomes is gaining traction, this specific approach in the context of palliative radiotherapy is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Planned to receive palliative radiotherapy for pain * Known cancer diagnosis * Able to wear Hexoskin Medical Shirt * Ability to use and populate the mobile app (Zamplo) with or without assistance * ECOG: 0-3 * Willing to provide a list of analgesic (pain relief) medication * Willing to complete questionnaires * Life expectancy of at least 3 months Exclusion Criteria: * Receiving whole brain radiotherapy * Major cognitive or psychiatric impairments * Pregnant women * Allergies to: polyester, synthetic fibers * Patients with pacemakers or implantable cardioverter-defibrillator (ICD) * Patients on a Holter Monitor
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Philip Wong — The Princess Margaret Cancer Foundation
- Study coordinator: Philip Wong
- Email: philip.wong@rmp.uhn.ca
- Phone: 416-946-4501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IL-15–Enhanced NK Cell Therapy for Solid Tumors
A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.
-
LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases
This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.
-
Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer
This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.
-
Support program for parents living with advanced cancer
This study tests whether adding experiential sessions to a psycho-educational program helps parents with advanced cancer communicate better with their children aged 10–25.
-
POLARIS — Ablative radiotherapy with immunotherapy for people with multiple metastatic lesions
This pilot tests whether giving focused high-dose radiation to up to 10 metastatic tumors while patients are on immunotherapy helps people with advanced solid tumors who have 3–10 metastases.
-
Adding Y‑NM600 imaging and targeted Y‑90 radiation to anti‑PD‑1/PD‑L1 treatment for metastatic cancer
This will test whether giving radioactive Y‑NM600 imaging and a targeted Y‑90 radiation dose to people with metastatic cancer who are on anti‑PD‑1 or anti‑PD‑L1 medicines is safe and can help those medicines work better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.